Revvity said revenue for Q2 2025 ended June 29, 2025 was $720.3 million, an increase of $28.6 million, or approximately 4%, compared to the same period in the prior year. Life Sciences segment revenue was $365.9 million and Diagnostics segment revenue was $354.4 million.

10-QQuarterly reportFiled Aug 5, 2025Period of report Jun 29, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

Revvity said revenue for Q2 2025 ended June 29, 2025 was $720.3 million, an increase of $28.6 million, or approximately 4%, compared to the same period in the prior year. Life Sciences segment revenue was $365.9 million and Diagnostics segment revenue was $354.4 million.
Revvity said gross margin for Q2 2025 was 54.5%, down 123 basis points from 55.7% in the prior-year quarter. The company cited increased tariffs, unfavorable changes in foreign exchange rates and product mix shift as factors, with pricing actions partially offsetting these.
Revvity said net cash provided by continuing operations for the 6 months ended June 29, 2025 was $268.4 million, a decrease from $332.5 million in the same period in the prior year. During the same period, the company used $447.5 million for share repurchases.
The company estimated that pursuant to tariffs currently in effect, its cost of revenue for the current fiscal year could increase by approximately $25 million. It said that reflecting mitigating actions, the tariffs would result in a decrease to gross margin for the current fiscal year of approximately $20 million.

Key figures

Quarter ended June 29, 2025

Revenue: $720M
Operating income: $91M
Net income: $54M
EPS: $0.46

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q2 2025 Revenue $720.3 million

Revvity said revenue for Q2 2025 ended June 29, 2025 was $720.3 million, an increase of $28.6 million, or approximately 4%, compared to the same period in the prior year. Life Sciences segment revenue was $365.9 million and Diagnostics segment revenue was $354.4 million.

Source · Based on the MD&A text of the filing

Q2 Gross Margin 54.5%, Tariff Impact

Revvity said gross margin for Q2 2025 was 54.5%, down 123 basis points from 55.7% in the prior-year quarter. The company cited increased tariffs, unfavorable changes in foreign exchange rates and product mix shift as factors, with pricing actions partially offsetting these.

Source · Based on the MD&A text of the filing

6-Month Operating Cash Flow and Share Repurchases

Revvity said net cash provided by continuing operations for the 6 months ended June 29, 2025 was $268.4 million, a decrease from $332.5 million in the same period in the prior year. During the same period, the company used $447.5 million for share repurchases.

Source · Based on the MD&A text of the filing

Tariff Impact Estimate and Mitigation Strategy

The company estimated that pursuant to tariffs currently in effect, its cost of revenue for the current fiscal year could increase by approximately $25 million. It said that reflecting mitigating actions, the tariffs would result in a decrease to gross margin for the current fiscal year of approximately $20 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.